Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
her2bbζ/cd19t+ t cells Acute Myeloid Leukemia	David Avigan	P1/2	CCC (49)
msc11fcd Glioblastoma	CHA University	P1/2	CCC (49)
Tcr-T Cells Hepatocellular Carcinoma	Lion TCR Pte. Ltd.	P1/2	CCC (49)
Tisagenlecleucel Leukemia	Stanford University	P1/2	CCC (49)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Autologous Dendritic Cell/Tumor Antigen, Adcta Hepatocellular Carcinoma	Chang Gung Memorial Hospital	P2	CCC (48)
Autologous Hb-Admscs Multiple Sclerosis	Hope Biosciences Research Foundation	P2	CCC (48)
Axicabtagene Ciloleucel Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals	P2	CCC (48)
Brexucabtagene Autoleucel Acute Lymphoblastic Leukemia	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
Breyanzi Injectable Product Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
cd22/cd19 car-t cell immunotherapy Lymphoma	Liping Dou	P2	CCC (48)
cd45ra-depleted dli Hodgkins Lymphoma	St. Jude Children's Research Hospital	P2	CCC (48)
cd70.car nk cells Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (48)
Chimeric Antigen Receptor Modified T Cells Infusion Mantle Cell Lymphoma	Canadian Cancer Trials Group	P2	CCC (48)
Cytokine-Induced Memory-Like Nk Cells Myelodysplastic Syndrome	Washington University School of Medicine	P2	CCC (48)
Dc-Cik Melanoma	The First People's Hospital of Changzhou	P2	CCC (48)
Dendritic Cell Tumor Fusion Fallopian Tube Cancer	Beth Israel Deaconess Medical Center	P2	CCC (48)
Descartes-08 Plasma Cell Myeloma	Cartesian Therapeutics	P2	CCC (48)
Dilanubicel Acute Biphenotypic Leukemia	Fred Hutchinson Cancer Center	P2	CCC (48)
Dilanubicel Myelodysplastic Syndrome With Excess Blasts	Fred Hutchinson Cancer Center	P2	CCC (48)
Dilanubicel Myelodysplastic Syndrome With Single Lineage Dysplasia	Fred Hutchinson Cancer Center	P2	CCC (48)
HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Igv-001 Cell Immunotherapy Glioblastoma	Imvax	P2	CCC (48)
Inaticabtagene Autoleucel Acute Lymphoblastic Leukemia	First Affiliated Hospital of Zhejiang University	P2	CCC (48)
Jwcar029 Follicular Lymphoma	Sun Yat-sen University	P2	CCC (48)

Showing 576 to 600 of 3,774 assets

PreviousPage 24 of 151Next